FOLH1 and prostate cancer: On the other hand, the introduction of a 4-(p-iodophenyl)butyric acid derivatives showed promising in vivo results using [177Lu]Lu-folates-cm10 for radionuclide therapy of folate receptor α (FR)-positive cancer and [177Lu]-PSMA-ALB-2 for prostate cancer therapy [33,34].